PTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 7,333 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 7,333 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $74.50, for a total transaction of $546,308.50. Following the sale, the director directly owned 6,666 shares in the company, valued at approximately $496,617. This trade represents a 52.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Emma Reeve also recently made the following trade(s):

• On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.50, for a total value of $1,088,787.00.
• On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.96, for a total value of $1,686,069.52.
• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total value of $934,447.50.

PTC Therapeutics Trading Up 0.5%

NASDAQ:PTCT traded up $0.35 on Friday, hitting $75.30. 922,380 shares of the company’s stock traded hands, compared to its average volume of 1,121,578. The company has a market cap of $6.05 billion, a PE ratio of 10.80 and a beta of 0.60. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $76.80. The firm has a 50-day moving average price of $65.29 and a 200-day moving average price of $54.46.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same period last year, the company posted ($1.39) earnings per share. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of research reports. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. TD Cowen upped their target price on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Citigroup lifted their price target on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. UBS Group increased their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Finally, Morgan Stanley reduced their target price on shares of PTC Therapeutics from $76.00 to $71.00 and set an “overweight” rating for the company in a research note on Wednesday, August 20th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.40.

Institutional Trading of PTC Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Creative Planning raised its holdings in PTC Therapeutics by 24.6% in the 3rd quarter. Creative Planning now owns 30,924 shares of the biopharmaceutical company’s stock worth $1,898,000 after acquiring an additional 6,107 shares during the period. SummitTX Capital L.P. grew its position in shares of PTC Therapeutics by 638.7% in the third quarter. SummitTX Capital L.P. now owns 102,734 shares of the biopharmaceutical company’s stock valued at $6,305,000 after purchasing an additional 88,826 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of PTC Therapeutics in the third quarter worth about $2,565,000. Wellington Management Group LLP lifted its position in shares of PTC Therapeutics by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock worth $301,856,000 after purchasing an additional 224,481 shares during the last quarter. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in PTC Therapeutics during the 3rd quarter valued at approximately $202,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.